Astra Pledges $50 Billion on US Manufacturing, Development

AstraZeneca Plc plans to invest $50 billion in the US before 2030, ratcheting up spending alongside other European drugmakers ahead of potential tariffs on imported medicines.

The investment will go toward manufacturing as well as research and development, Astra said in a statement. It includes $4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said Monday at an event in Washington, DC.